Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Los Angeles Times - November 11, 2006
Jia-Rui Chong, jia-rui.chong@latimes.com
In the five HIV-infected patients in the study, the amount of virus remained stable or decreased. The number of T cells - immune cells that fight the virus - held steady or increased in four of five patients.
Tests showed no dangerous, mutated forms of the genetically modified virus in the body, said Bruce Levine, lead author of the paper published Tuesday in the Proceedings of the National Academy of Sciences.
Levine, an immunologist at the University of Pennsylvania, said none of the patients, who received the treatment two to three years ago, had developed leukemia or other problems that had afflicted patients in other gene therapy studies.
"Although gene therapy has had setbacks ... this shows the slope of steady progress we're making," he said.
The Penn group collaborated with scientists at Virxsys Corp., a Gaithersburg, Md., biotechnology firm that developed the modified version of HIV, called VRX496.
The study was funded by Virxsys, the National Institute of Allergy and Infectious Disease and the Abramson Family Cancer Research Institute.
Levine's group gathered T cells from five subjects who had failed to improve using combination drug treatments. The cells were mixed with the altered virus, which was designed to attach itself into the genetic material of the T cell and block replication of the full HIV genome.
"We used the modified HIV as a Trojan horse to deliver something that throws a monkey wrench in the natural replication process," Levine said.
Researchers reinfused the patients with about 10 billion modified T cells.
In one subject, the treatment cut the amount of virus in his blood by a factor of about 50 at the end of 12 months.
"It's a promising start and worthy of trials to figure out if it's going to work," Levine said.
061111
LT061103
Copyright © 2006 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .